Richard Alan Rudick Acquires 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) Stock

Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now directly owns 87,300 shares in the company, valued at $100,395. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Immunic Trading Up 1.7 %

IMUX opened at $1.17 on Thursday. The firm’s 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.35. The company has a market capitalization of $105.39 million, a PE ratio of -0.95 and a beta of 1.88. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently bought and sold shares of IMUX. BVF Inc. IL bought a new stake in Immunic during the 1st quarter worth approximately $11,752,000. Janus Henderson Group PLC purchased a new stake in shares of Immunic in the first quarter worth $9,266,000. Vanguard Group Inc. increased its stake in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC lifted its stake in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IMUX. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partners restated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Monday. Finally, B. Riley initiated coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective for the company. One analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic currently has a consensus rating of “Buy” and an average target price of $11.20.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.